0.22-Micron Sterilizing-Grade Membrane Filters

German science and technology company (Darmstadt; family-owned since 1668; €22B revenue); life science division (MilliporeSigma in US/Canada, Millipore globally) is the world's leading producer of pharmaceutical sterilizing-grade membrane filters under the Durapore® (PVDF), Millipak®, and Express® SHC brands. Durapore 0.22 μm PVDF filters are the industry benchmark for IV fluid sterilizing filtration — validated by virtually every major IV fluid manufacturer globally. Merck KGaA has been family-controlled since 1668 — making it the world's oldest operating pharmaceutical company (predating most European nations in their current form). The Merck family still controls >70% of shares through their foundation. The same 350-year-old German family company that supplied dyes to the First World War German army now makes the sterilizing filters that make every IV bag sterile. Note: US Merck (MSD/Merck & Co.) is a separate company that split from Merck KGaA after World War I when its US subsidiary was seized as enemy property and sold.

American filtration, separation, and purification technology company (Port Washington, NY; Danaher Corporation subsidiary since 2015 acquisition for $13.8B); world's second-largest pharmaceutical sterilizing filter manufacturer under the Supor® (PES), Fluorodyne® EX (PVDF), and Emflon® (PTFE) brands. Pall Corporation was founded in 1946 by Dr. David Pall, a British-born scientist who invented the first practical fluid filtration membrane for aircraft jet fuel systems during WWII — technology originally developed for military aviation now forms the basis of pharmaceutical sterile filtration. Pall's acquisition by Danaher — which also owns Cytiva (former GE Healthcare Life Sciences, bioreactors and chromatography) — means a single US conglomerate controls approximately 35-40% of the critical tools and materials used in both IV fluid manufacturing and biopharmaceutical drug production.

German laboratory and bioprocessing equipment company (Göttingen; XETRA: SRT; ~€3.4B revenue) that manufactures Sartopore 2 (PES — polyethersulfone) and Sartopore Platinum (modified PES) sterilizing membranes — the primary European alternative to Merck/Pall membrane platforms. Sartorius holds an estimated ~15% share of the pharmaceutical sterilizing filtration market, with particular strength in European biologics manufacturing. Sartorius also makes Sartocon cassette systems for tangential flow filtration (TFF), Stedim biocontainers (single-use bags), and Biowave bioreactor systems — making it, like Danaher, a vertically integrated supplier across multiple critical biopharmaceutical manufacturing unit operations. Sartorius acquired Stedim (France) in 2007 and has organically grown its bioprocessing portfolio. Göttingen primary manufacturing; additional production in Yauco, Puerto Rico (acquired via Sartorius Stedim Biotech).